1,436 reports of this reaction
1.9% of all SILDENAFIL POWDER, reports
#10 most reported adverse reaction
PULMONARY ARTERIAL HYPERTENSION is the #10 most commonly reported adverse reaction for SILDENAFIL POWDER,, manufactured by ANI Pharmaceuticals, Inc.. There are 1,436 FDA adverse event reports linking SILDENAFIL POWDER, to PULMONARY ARTERIAL HYPERTENSION. This represents approximately 1.9% of all 76,536 adverse event reports for this drug.
SILDENAFIL POWDER, has an overall safety score of 85 out of 100. Patients taking SILDENAFIL POWDER, who experience pulmonary arterial hypertension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY ARTERIAL HYPERTENSION is a less commonly reported adverse event for SILDENAFIL POWDER,, but still significant enough to appear in the safety profile.
In addition to pulmonary arterial hypertension, the following adverse reactions have been reported for SILDENAFIL POWDER,:
The following drugs have also been linked to pulmonary arterial hypertension in FDA adverse event reports:
PULMONARY ARTERIAL HYPERTENSION has been reported as an adverse event in 1,436 FDA reports for SILDENAFIL POWDER,. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY ARTERIAL HYPERTENSION accounts for approximately 1.9% of all adverse event reports for SILDENAFIL POWDER,, making it a notable side effect.
If you experience pulmonary arterial hypertension while taking SILDENAFIL POWDER,, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.